Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.39 |
| ▸ | BCR | P11274 | 4/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197671 | 0.84 | GRM5 (0.64) | GRM5CYP2A6MEN1 | |
| SCHEMBL5473528 | 0.79 | GRM5 (0.70) | GRM5KDRCYP2A6 | |
| SCHEMBL5202900 | 0.78 | MIF (0.42) | GRM5KDRKIF11ABL1BCR | |
| SCHEMBL14409173 | 0.78 | GRM5 (0.57) | GRM5KDRKIF11ABL1BCR | |
| SCHEMBL5202470 | 0.76 | GRM5 (0.67) | GRM5MAPTPIK3CAPIK3CG | |
| SCHEMBL5204644 | 0.73 | GRM5 (1.00) | GRM5 | |
| SCHEMBL4908113 | 0.72 | KIF11 (0.57) | KDRKIF11ABL1MAPTNPC1 | |
| SCHEMBL5204260 | 0.71 | GRM5 (0.54) | GRM5 | |
| SCHEMBL8353812 | 0.69 | GRM5 (0.53) | GRM5KDM4EDRD2DRD4DRD3 | |
| SCHEMBL30103987 | 0.69 | CNR1 (0.56) | ABL1BCRMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458708-B1 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-09-26 | — | — | EP | claimed |
| US-7105548-B2 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | claimed |
| EP-1458708-A4 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | claimed |
| EP-1458708-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003051315-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | claimed |
| EP-1458708-B1 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7105548-B2 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | disclosed |
| WO-2003051315-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN3A | GRM5 1/4885KDR 3896/4885KIF11 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.